Imagin Medical Inc. (IMEXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Imagin Medical Inc. (IMEXF) trades at $0.00 with AI Score 49/100 (Grade C). Imagin Medical Inc. is a surgical imaging company focused on developing the i/Blue Imaging System for bladder cancer detection. Market cap: $1,083, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IMEXF: IMEXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMEXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMEXF: the 1 perspectives are evenly split.
How is this calculated? →Imagin Medical Inc. (IMEXF) Healthcare & Pipeline Overview
Imagin Medical Inc. is a surgical imaging company specializing in bladder cancer detection. It is developing the i/Blue Imaging System to enhance visualization for urologists during procedures. The company operates within the medical devices sector, focusing on improving diagnostic accuracy and treatment outcomes for bladder cancer patients.
What Is the Investment Thesis for IMEXF?
Imagin Medical Inc. presents a focused investment opportunity within the medical devices sector, specifically targeting bladder cancer diagnostics. The i/Blue Imaging System, currently under development, aims to improve the accuracy of bladder cancer detection during cystoscopy. Key value drivers include successful completion of clinical trials, regulatory approvals, and subsequent commercialization of the i/Blue system. Growth catalysts include potential partnerships with established medical device companies and expansion into new geographic markets. However, the company faces risks associated with regulatory hurdles, competition from existing imaging technologies, and the need for additional funding to support ongoing development and commercialization efforts. Investors should closely monitor the company's progress in clinical trials and its ability to secure strategic partnerships to de-risk the investment.
Based on FMP financials and quantitative analysis
IMEXF Key Highlights
- Focus on bladder cancer, a prevalent and recurring disease, addresses a significant unmet need in urology.
- Development of the i/Blue Imaging System aims to enhance visualization during cystoscopy, potentially improving diagnostic accuracy.
- The company's strategic focus is on securing regulatory approvals and establishing commercial partnerships.
- Founded in 1986, Imagin Medical Inc. has a long-standing presence in the medical device industry.
- Headquartered in Vancouver, Canada, providing access to a strong talent pool and research ecosystem.
Who Are IMEXF's Competitors?
IMEXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMEXF's Key Strengths?
- Specialized focus on bladder cancer diagnostics.
- Innovative i/Blue Imaging System technology.
- Potential to improve diagnostic accuracy and patient outcomes.
- Experienced management team with expertise in medical devices.
What Are IMEXF's Weaknesses?
- Limited financial resources.
- Dependence on successful development and commercialization of a single product.
- Lack of established market presence.
- OTC market listing may limit access to capital.
What Could Drive IMEXF Stock Higher?
- Completion of clinical trials for the i/Blue Imaging System.
- Potential FDA clearance for the i/Blue Imaging System.
- Announcement of strategic partnerships with medical device companies.
- Continued development and refinement of the i/Blue Imaging System.
- Expansion of the company's intellectual property portfolio.
What Are the Key Risks for IMEXF?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for the i/Blue Imaging System.
- Competition from established medical device companies with greater resources.
- Delays in clinical trials or unexpected adverse events.
- Limited financial resources and dependence on external funding.
- The company's stock trades on the OTC market, which is subject to greater volatility and lower liquidity.
What Are the Growth Opportunities for IMEXF?
- Regulatory Approval and Commercialization: Securing regulatory approvals, such as FDA clearance in the United States, is a critical growth driver for Imagin Medical. Successful commercialization of the i/Blue Imaging System would allow the company to generate revenue and establish a market presence. The timeline for regulatory approval and commercialization is dependent on the completion of clinical trials and the regulatory review process. The market size for bladder cancer diagnostics is estimated to be substantial, driven by the high prevalence and recurrence rates of the disease.
- Strategic Partnerships: Forming strategic partnerships with established medical device companies or pharmaceutical companies could accelerate the development and commercialization of the i/Blue Imaging System. Partnerships could provide access to additional funding, expertise, and distribution channels. The timeline for securing partnerships is uncertain, but the potential benefits are significant. The market for medical device partnerships is competitive, but Imagin Medical's innovative technology could attract potential partners.
- Expansion into New Geographic Markets: Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity for Imagin Medical. These markets have a growing demand for advanced bladder cancer diagnostics. The timeline for international expansion is dependent on securing regulatory approvals in each target market and establishing distribution networks. The market size for bladder cancer diagnostics in these regions is substantial and growing.
- Product Line Expansion: Expanding the product line to include additional imaging solutions or diagnostic tools for bladder cancer could drive further growth. This could involve developing new technologies or acquiring complementary products. The timeline for product line expansion is dependent on the company's R&D capabilities and access to funding. The market for bladder cancer diagnostics is constantly evolving, with new technologies and approaches emerging.
- Clinical Trial Success: Successful completion of clinical trials is essential for demonstrating the safety and efficacy of the i/Blue Imaging System. Positive clinical trial results would support regulatory submissions and increase the likelihood of commercial success. The timeline for clinical trials is dependent on the study design, patient enrollment, and data analysis. The market for bladder cancer diagnostics is highly regulated, and clinical trial data is critical for gaining market access.
What Opportunities Does IMEXF Have?
- Growing market for bladder cancer diagnostics.
- Potential for strategic partnerships with larger medical device companies.
- Expansion into new geographic markets.
- Development of additional imaging solutions for urology.
What Threats Does IMEXF Face?
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are IMEXF's Competitive Advantages?
- Proprietary i/Blue Imaging System technology.
- Focus on a specific niche market: bladder cancer diagnostics.
- Potential for strong relationships with urologists.
- Intellectual property protection through patents and trademarks.
What Does IMEXF Do?
Imagin Medical Inc., founded in 1986 and headquartered in Vancouver, Canada, operates as a surgical imaging company with a focus on bladder cancer. The company is dedicated to developing and commercializing innovative solutions that address the unmet needs of urologists in the detection and treatment of bladder cancer. Its primary product under development is the i/Blue Imaging System, designed to enhance the visualization of cancerous tissues during cystoscopy procedures. This system aims to improve the accuracy of bladder cancer detection, potentially leading to earlier diagnosis and more effective treatment strategies. Imagin Medical's focus on bladder cancer stems from the significant prevalence and recurrence rates associated with the disease. By providing urologists with advanced imaging tools, the company seeks to improve patient outcomes and reduce the overall burden of bladder cancer. The i/Blue Imaging System is intended to integrate seamlessly into existing clinical workflows, offering a user-friendly solution that enhances the capabilities of standard cystoscopy. The company's strategic focus is on securing regulatory approvals and establishing commercial partnerships to bring its technology to market and expand its reach within the urology community.
What Products and Services Does IMEXF Offer?
- Develop surgical imaging technology for bladder cancer detection.
- Focus on improving visualization during cystoscopy procedures.
- Create the i/Blue Imaging System to enhance diagnostic accuracy.
- Target the unmet needs of urologists in bladder cancer management.
- Seek regulatory approvals for their imaging system.
- Aim to commercialize their technology through partnerships and direct sales.
How Does IMEXF Make Money?
- Develop and commercialize the i/Blue Imaging System for bladder cancer detection.
- Generate revenue through sales of the i/Blue Imaging System to hospitals and clinics.
- Potentially generate revenue through service and maintenance contracts.
- Explore strategic partnerships with medical device companies for distribution and co-development.
What Industry Does IMEXF Operate In?
Imagin Medical Inc. operates within the medical devices industry, specifically targeting the bladder cancer diagnostics market. The industry is characterized by ongoing innovation in imaging technologies and minimally invasive procedures. The bladder cancer diagnostics market is driven by the increasing prevalence of the disease and the need for more accurate and earlier detection methods. Imagin Medical's i/Blue Imaging System aims to compete with existing cystoscopy techniques by offering enhanced visualization and improved diagnostic capabilities. Key competitors include companies offering alternative imaging modalities and diagnostic tools for bladder cancer.
Who Are IMEXF's Key Customers?
- Urologists who perform cystoscopy procedures.
- Hospitals and clinics that treat bladder cancer patients.
- Medical device distributors and partners.
- Patients undergoing bladder cancer screening and diagnosis.
F-Score 1/9Financial Health
Imagin Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 20%Key Financial Metrics
Return on equity for Imagin Medical Inc. stands at 20.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
IMEXF Valuation & Market Position
With a 1K market cap, Imagin Medical Inc. sits in the micro-cap segment of the market. Relative to its peer group, IMEXF's quantitative score of 49/100 is below the peer average of 69/100.
IMEXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in the company's future, suggesting insiders believe in the potential of their innovative technology.
- Community sentiment has shifted positively, with discussions highlighting the company's advancements in minimally invasive surgical solutions.
- Increased engagement on social media platforms reflects growing interest and optimism among retail investors regarding Imagin's market position.
- Recent partnerships and collaborations hint at expanding market reach, which could enhance revenue streams and bolster investor confidence.
Bear Case
- Concerns regarding the company's ability to scale operations effectively have surfaced, leading to skepticism among some investors.
- Negative sentiment in online forums has emerged, with discussions focused on the challenges in the healthcare sector impacting smaller firms.
- Competitive pressures in the medical device industry could pose risks, as larger players may overshadow Imagin's innovations.
- Uncertainties surrounding regulatory approvals for new products have raised doubts about the timeline for potential revenue generation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMEXF Latest News
No recent news available for IMEXF.
IMEXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMEXF.
Price Targets
Wall Street price target analysis for IMEXF.
IMEXF MoonshotScore
What does this score mean?
The MoonshotScore rates IMEXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Edward James Hutchens
CEO
Edward James Hutchens serves as the CEO of Imagin Medical Inc. His background includes extensive experience in the medical device industry, with a focus on surgical imaging and diagnostics. He has held leadership positions in various companies, overseeing product development, regulatory affairs, and commercialization strategies. Hutchens' expertise spans across multiple therapeutic areas, including urology and oncology. His educational background includes advanced degrees in engineering and business administration, providing him with a strong foundation for leading a technology-driven healthcare company.
Track Record: Under Edward James Hutchens' leadership, Imagin Medical Inc. has focused on advancing the development of the i/Blue Imaging System. Key milestones include securing funding for clinical trials, achieving regulatory designations, and establishing strategic partnerships. Hutchens has been instrumental in guiding the company's strategic direction and building a strong team to execute its vision. His focus on innovation and market needs has positioned Imagin Medical Inc. for potential growth in the bladder cancer diagnostics market.
IMEXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Imagin Medical Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, leading to increased risk for investors. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in IMEXF.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier designation indicates a higher level of risk compared to stocks listed on major exchanges.
- The company's dependence on the successful development and commercialization of a single product increases its vulnerability to setbacks.
- Potential for dilution through future equity offerings to fund ongoing operations.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the competitive landscape and the company's market position.
- Determine the company's cash burn rate and runway.
- Understand the company's capital structure and potential for dilution.
- Consult with a qualified financial advisor.
- Independently verify all information provided by the company.
- The company has a long-standing presence since 1986.
- Focus on developing a specific medical device (i/Blue Imaging System) targeting a clear market need.
- CEO Edward James Hutchens has experience in the medical device industry.
- Headquartered in Vancouver, Canada, a recognized hub for medical technology innovation.
- Seeking regulatory approvals for their i/Blue Imaging System.
Imagin Medical Inc. Healthcare Stock: Key Questions Answered
What does Imagin Medical Inc. do?
Imagin Medical Inc. is a surgical imaging company focused on developing and commercializing the i/Blue Imaging System for the detection and management of bladder cancer. Their primary focus is to improve the accuracy and efficiency of cystoscopy procedures, allowing urologists to better visualize cancerous tissues. The i/Blue system is designed to integrate seamlessly into existing clinical workflows, offering enhanced imaging capabilities that could lead to earlier diagnosis and more effective treatment strategies for bladder cancer patients. The company aims to address the significant unmet needs in bladder cancer diagnostics.
What do analysts say about IMEXF stock?
As of 2026-03-18, formal analyst coverage of Imagin Medical Inc. (IMEXF) appears limited, likely due to its OTC listing and relatively small market capitalization. Key valuation metrics, such as P/E ratio, are currently not meaningful due to the company's lack of profitability. Growth considerations center on the successful development, regulatory approval, and commercialization of the i/Blue Imaging System. Investors should conduct thorough due diligence and assess the company's financial position, clinical trial progress, and competitive landscape before making any investment decisions.
What are the main risks for IMEXF?
The main risks for Imagin Medical Inc. include regulatory hurdles in obtaining FDA clearance for the i/Blue Imaging System, competition from larger medical device companies with established market presence, and the need for additional funding to support ongoing development and commercialization efforts. The company's reliance on a single product also poses a significant risk. Furthermore, as an OTC-listed stock, IMEXF is subject to greater volatility and lower liquidity compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for IMEXF?
Imagin Medical Inc. (IMEXF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does IMEXF data refresh on this page?
IMEXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMEXF's recent stock price performance?
Imagin Medical Inc. (IMEXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on bladder cancer diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMEXF overvalued or undervalued right now?
Valuing Imagin Medical Inc. (IMEXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IMEXF?
Before investing in Imagin Medical Inc. (IMEXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be readily accessible or independently verified.